← Eichor
Condition: Follicular Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Follicular Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Zanubrutinib Combined With G-CVP in Previously Untreated FL
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06959732AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT07545603Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07293403Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Phase 3 · 116 location(s) · The Lymphoma Academic Research Organisation · NCT06284122The "Let's Talk Tech" Tool to Support Decision Making About Technology Use
NA · 1 location(s) · University of Washington · NCT06817122A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease P
Phase 2 · 2 location(s) · Elixiron Immunotherapeutics Inc. · NCT06745583Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
NA · 1 location(s) · University of Washington · NCT02537769A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06043323Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Phase 2 · 3 location(s) · Beth Israel Deaconess Medical Center · NCT06510361Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06471738Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
Phase 2 · 1 location(s) · Peking University · NCT06347653Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07126678This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · 6 location(s) · LTZ Therapeutics, Inc. · NCT07121946Remission in Adults With Severe Asthma in Thailand
Phase N/A · 1 location(s) · Thammasat University · NCT07328035Odronextamab in Low Tumor Volume Advanced FL
Phase 2 · 1 location(s) · Gottfried von Keudell, MD PhD · NCT07128641Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular H
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05572983Cognitive Screening Made Easy for PCPs - Administrative Supplement
NA · 3 location(s) · University of Texas at Austin · NCT06928298CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
Phase 2 · 1 location(s) · Liping Dou · NCT07587840Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · 51 location(s) · Miltenyi Biomedicine GmbH · NCT04844866Preventive Application of Single-use Negative Pressure Wound Therapy (sNPWT) in the Postoperative Course of Radiotreatat
NA · 1 location(s) · Istituto Oncologico Veneto IRCCS · NCT06941194The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06704555Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Phase 1/Phase 2 · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05326243Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05672251Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
Phase 2 · 2 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07299149
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.